Ankylosing spondylitis is a long-term inflammatory disease that primarily affects the spine. It causes pain and stiffness in the lower back and neck. The disease causes inflammation of joints which connect the spine to the pelvis. This chronic inflammatory condition causes swelling of tendons and ligaments leading to stiffness and fusion of the spinal vertebrae over a period of time.
The Global Ankylosing Spondylitis Treatment Market is estimated to be valued at US$ 4,864.3 Billion in 2021 and is expected to exhibit a CAGR of 8.2% over the forecast period 2021 to 2028.
Key Takeaways
Key players operating in the ankylosing spondylitis market are Pfizer, Merck & Co., Novartis, UCB, Amgen, Johnson & Johnson Services, AbbVie, Eli Lilly and Company, and Celgene Corporation.
The prevalence of Ankylosing Spondylitis Market Size is growing significantly across the globe which is fueling the market growth. According to the spondylitis association of America, over two million people suffer from ankylosing spondylitis worldwide. The rising diagnosis and treatment rates are expected to drive the market during the forecast period.
Technological advancements are being made in drug development for ankylosing spondylitis. Companies are conducting extensive research to develop biological treatments with novel mechanisms of action. Biologics have revolutionized the treatment of AS and are enabling better management of symptoms. This is positively impacting the market.
Market Trends
Increasing use of biosimilars - Patent expiration of biologics is providing opportunities for biosimilar drugs to enter the market. This is bringing down treatment costs and increasing accessibility to patients.
Growing pipeline of drugs - Many companies are exploring targeted treatment options against new disease pathways. Drugs in phase III trials include abivertinib, mirikizumab, and filgotinib which hold promise.
Rising awareness - Initiatives by government and nonprofit organizations are helping improve awareness about early symptoms and management of ankylosing spondylitis. This is encouraging more people to seek medical help.
Market Opportunities
Untapped emerging markets - Asia Pacific and Latin America markets offer significant growth potential due to rising healthcare spending and large patient pools.
Novel drug delivery technologies - Areas such as controlled release injectables, transdermal systems could enhance treatment adherence and give convenience advantages over oral formulations.
Impact of COVID-19 on Ankylosing Spondylitis Market Growth
The COVID-19 pandemic has disrupted the growth trajectory of the ankylosing spondylitis market. With lockdowns enforced worldwide, patients faced difficulties in accessing routine check-ups and prescribed treatments. This led to interrupted care and management of the chronic inflammation of the spine and other joints. Telehealth emerged as a viable solution to ensure continuity of care. However, virtual consultations could not replace in-person examinations needed for ankylosing spondylitis. Furthermore, supply chain disturbances due to halted manufacturing and trade flows resulted in shortages and stock-outs ofkey drugs such as anti-TNF agents and NSAIDsused for ankylosing spondylitis.
As the pandemic continues, it remains crucial for healthcare providers and policymakers to adopt mitigationstrategies that prioritize ankylosing spondylitis patients. Telemedicine must be further streamlinedand integrated into treatment protocols. Contingency plans should be developed to avoid future drug supply issues. Support groups can help patients cope with the psychological impact of prolonged social isolationand uncertainty. Once the crisis abates, focus on rheumatology services may be needed to address treatment gapsformedduring the pandemic. The market is expected to rebound steadily as normalcy resumes in clinical managementand drug supplies.
Geographical Regions with High Market Concentration
The North American region accounts for a majorvalue share in the global ankylosing spondylitis market. This is attributed to the presence of developed healthcare systems and high disease prevalence inthe United States and Canada. According to estimates, over 300,000 Americans suffer from ankylosing spondylitis. Favorable reimbursement policies for biologicshave encouraged treatment uptake. Similarly, countriesacross Western Europe such as Germany, France and the UKaccount for a significant proportion of market revenues due to growing patient pools and accessibility of advanced care options.
Fastest Growing Regional Market
The Asia Pacific region is expected witness the fastestgrowthin the ankylosing spondylitis market during the forecast period. This can be accredited to evolving healthcare infrastructure, economic development and risingmedicaltourism across emerging nations like China, India and South Korea. Improving access to novel targeted therapiesis augmenting demand. Moreover, growing disease awareness pairedwith large undiagnosed populations indicate strong marketpotential. Initiatives aimed at early diagnosisand affordable biologics are likely tosupport continued expansion of the APAC ankylosing spondylitis market.
Get more insights on, Ankylosing Spondylitis Market
Get This Report in Japanese Language: ๅผท็ดๆง่ๆค็ๅธๅ ด
Get This Report in Korean Language: ๊ฐ์ง์ฑ ์ฒ์ถ์ผ ์์ฅ
About Author:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. (LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)
